AB Science SA

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

29 Feb 2024 04:49:23 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

26 Feb 2024 11:32:14 By Nasdaq GlobeNewswire

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

26 Jan 2024 11:01:21 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

15 Jan 2024 11:06:57 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

28 Nov 2023 12:22:40 By Nasdaq GlobeNewswire

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

27 Nov 2023 01:04:30 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

29 Sep 2023 12:49:30 By Nasdaq GlobeNewswire

AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

18 Sep 2023 11:05:35 By Nasdaq GlobeNewswire

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

26 Jun 2023 11:11:42 By Nasdaq GlobeNewswire

AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

01 Jun 2023 11:01:02 By Nasdaq GlobeNewswire

AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

17 May 2023 13:14:57 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

09 May 2023 11:06:29 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2022 and provides an update on its activities

28 Apr 2023 11:41:27 By Nasdaq GlobeNewswire

AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

27 Apr 2023 13:41:14 By Nasdaq GlobeNewswire

AB Science announces the success of its capital increase by private placement for an amount of 15 million euros

24 Apr 2023 01:05:09 By Nasdaq GlobeNewswire

AB Science announces the implementation of a new strategy and the launch of a capital increase

21 Apr 2023 15:26:19 By Nasdaq GlobeNewswire

AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

18 Apr 2023 11:55:51 By Nasdaq GlobeNewswire

AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline

12 Apr 2023 11:23:23 By Nasdaq GlobeNewswire

AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada

04 Apr 2023 11:10:02 By Nasdaq GlobeNewswire

AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET

15 Mar 2023 12:05:03 By Nasdaq GlobeNewswire